Month: September 2021

Psychedelic Drug Attracts Corporate Attention

n the United States, over 2 million Americans suffered from opioid addiction in 2018. With relapse rates of traditional rehabilitative models averaging at about 50%, companies have positioned themselves within the psychedelic drug sector to bring a different therapeutic approach. Companies such as ATAI Sciences and DemeRx are investigating ibogaine, a natural extract found in western Central Africa that has proven effective in reducing opioid withdrawal symptoms and cravings. Researchers also found that the same substance lessens depression that accompanies …

Read MorePsychedelic Drug Attracts Corporate Attention